Tampa General Hospital’s Stacey Brandt Named to Modern Healthcare 2024 Class of Women Leaders

Brandt, Tampa General Hospital’s EVP and chief administrative officer, was recognized among Modern Healthcare’s 2024 class of Women Leaders for her strategic leadership.

Stacey Brandt, executive vice president and chief administrative officer of Tampa General Hospital (TGH), was recognized as part of Modern Healthcare’s 2024 class of Women Leaders. Modern Healthcare, the leader in health care business news, research and data, annually honors influential women from all sectors of the health care industry who are making significant contributions to their organizations by developing policy, leading change and guiding improvements in care delivery.

“Stacey’s exceptional leadership and outstanding strategic acumen have directly driven significant organizational growth and capture of market share for Tampa General,” said John Couris, president and CEO of Tampa General Hospital. “This recognition underscores her national reputation as a collaborative, dedicated and visionary leader who has been instrumental in our transformation to become one of the nation’s leading academic and research-based health systems.”

At Tampa General, Brandt oversees the development and execution of the strategy, market planning and growth, marketing, public relations, physician business development, service lines, health care transformation, process engineering, external affairs, and project and program management for Florida Health Sciences Center, which comprises several organizations, including Tampa General. She also served as the architect of Tampa General’s five-year strategic plan and is leading the development of its next evolution, driving the planning process as well as overseeing its governance and execution.

With the implementation of Brandt’s strategic initiatives, Tampa General has seen increased patient volumes and market share across the academic health system’s primary service area year over year for the last several years. Over the course of five years, the organization’s market share grew from 19 percent to 24 percent, surpassing competitors to become the consistent market leader.

“It’s an honor to be recognized amongst an incredible list of women who are making lasting change in our industry and paving a way for a more equitable future for women in health care,” Brandt said. “I have the great privilege of working alongside a talented team of individuals who share in our strategic vision of the organization and I look forward to continuing to build on our legacy of excellence together.”

This latest recognition by Modern Healthcare follows several recent accolades for Brandt, including honors on Becker’s Hospital Review’s lists of Chief Marketing Officers of Hospitals and Health Systems to Know and Chief Strategy Officers of Hospitals and Health Systems to Know in 2023.

Brandt and the full 2024 class of Modern Healthcare Women Leaders are profiled in the print edition of the magazine, as well as online here.

ABOUT TAMPA GENERAL HOSPITAL

Tampa General Hospital, a 981-bed, not-for-profit, academic health system, is one of the largest hospitals in America and delivers world-class care as the region’s only center for Level l trauma and comprehensive burn care. Tampa General Hospital is the highest-ranked hospital in the market in U.S. News and World Report’s 2023-24 Best Hospitals, with six specialties ranking among the top 50 best hospital programs in the United States. Tampa General Hospital has been designated as a model of excellence by the 2022 Fortune/Merative 100 Top Hospitals list. The academic health system’s commitment to growing and developing its team members is recognized by two prestigious Forbes magazine rankings – in the top 100 nationally in the 2023 America’s Best Employers for Women and top 25 in Florida in the 2023 America’s Best Employers by State. Tampa General is the safety net hospital for the region, caring for everyone regardless of their ability to pay, and in fiscal year 2021, provided a net community benefit of approximately $240.3 million in the form of health care for underinsured patients, community education, and financial support to community health organizations in Tampa Bay. It is one of the nation’s busiest adult solid organ transplant centers and is the primary teaching hospital for the USF Health Morsani College of Medicine. With six medical helicopters, Tampa General Hospital transports critically injured or ill patients from 23 surrounding counties to receive the advanced care they need. Tampa General houses a nationally accredited comprehensive stroke center, and its 32-bed Neuroscience, Intensive Care Unit is the largest on the West Coast of Florida. It also is home to the Jennifer Leigh Muma 82-bed neonatal intensive care unit, and a nationally accredited rehabilitation center. Tampa General Hospital’s footprint includes TGH North which is comprised of three hospitals and several outpatient locations in Citrus and Hernando counties, 17 Tampa General Medical Group Primary Care offices, TGH Family Care Center Kennedy, TGH Outpatient Center, TGH Virtual Health, and 21 TGH Imaging outpatient radiology centers throughout Hillsborough, Pasco, Pinellas and Palm Beach counties. Tampa Bay area residents also receive world-class care from the TGH Urgent Care powered by Fast Track network of clinics. To see a medical care professional live anytime, anywhere on a smartphone, tablet or computer, visit Virtual Health | Tampa General Hospital (tgh.org). As one of the largest hospitals in the country, Tampa General Hospital is the first in Florida to partner with GE Healthcare and open a clinical command center that provides real-time situational awareness to improve and better coordinate patient care at a lower cost. 

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services